Clinical analysis of morphine hydrochloride sustainedrelease tablets combined with celecoxib in the treatment of advanced lung cancer with moderate to severe cancerinduced pain

Abstract

Abstract:ObjectiveTo explore the efficacy, safety and life quality of patients of morphine hydrochloride sustainedrelease tablets combined with celecoxib in the treatment of advanced lung cancer with moderate to severe cancerinduced pain. MethodsA total of 247 patients of advanced lung cancer with moderate to severe cancerinduced pain were randomly divided into combination therapy group (n=127) and morphine monotherapy group (n=120) using simple random sampling digital table method. The differences of dose, efficacy, adverse drug reactions and life quality between the two groups were analyzed. ResultsIn achieving similar analgesic effect, the average maintenance dose of morphine in combination therapy group was (52.51±19.92)mg/d, lower than that in monotherapy group ［(58.75±20.64)mg/d, t=-2.414, P=0.017］. The incidence of constipation in combination therapy group was 34.6%, lower than that in monotherapy treatment group (47.5%, χ2=4.218, P=0.040). The life quality of the two groups were improved, and the life quality improvement rate in combination therapy group was 59.8%, higher than that in monotherapy treatment group (43.3%, χ2=6.736, P=0.009). ConclusionMorphine hydrochloride sustainedrelease tablets combined with celecoxib is effective in the treatment of moderate to severe cancer pain, which can reduce the dosage of morphine and reduce adverse reaction, so as to improve the life quality of the patients with advanced lung cancer.

Key words:Lung neoplasms,Quality of life,Morphine,Celecoxib,Cancer pain

Li Xueqin, Chen Xi, Gong Quan, Shi Wei, Zhang Lijuan, Dong Hui, Wang Cunde. Clinical analysis of morphine hydrochloride sustainedrelease tablets combined with celecoxib in the treatment of advanced lung cancer with moderate to severe cancerinduced pain[J]. Journal of International Oncology, 2017, 44(3): 165-168.

References

［1］ Yu HS, Qu Y, Shang QJ, et al. The clinical effects of lowdose splenic irradiation combined with chest threedimensional conformal radiotherapy on patients with locally advanced nonsmallcell lung cancer: a randomized clinical trial［J］. Onco Targets Ther, 2016, 9(9): 55455552. DOI: 10.2147/OTT.S95992. ［2］ Masel EK, Schur S, Nemecek R, et al. Palliative care units in lung cancer in the realworld setting: a single institution′s experience and its implications［J］. Ann Palliat Med, 2016, 2017， 6（1）： 613. DOI: 10.21037/apm.2016.08.06. ［3］ Gartner R, Kroman N, Callesen T, et al. Multimodal prevention of pain, nausea and vomiting after breast cancer surgery［J］. Minerva Anestesiol, 2010, 76(10): 805813. ［4］ Trabulsi EJ, Patel J, Viscusi ER, et al. Preemptive multimodal pain regimenreduces opioid analgesia for patients undergoing roboticassistedlaparoscopic radical prostatectomy［J］. Urology, 2010, 76(5): 11221124. DOI: 10.1016/j.urology.2010.03.052. ［5］ Freedman BM, Balakrishnan TP, O′hara EL. Celecoxib reduces narcotic use and pain following augmentation mammaplasty［J］. Aesthet Surg J, 2006, 26(1): 2428. DOI: 10.1016/j.asj.2005.11.001. ［6］蔡讯, 薛鹏, 宋卫峰, 等. 硫酸吗啡控释片联合塞来昔布个体化治疗中重度癌痛的临床疗效及安全性［J］. 中国癌症杂志, 2009, 19(4): 270273. DOI: 10.3969/j.issn.10073639.2009.04.007. ［7］ Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE522, and conventional anticancer agents［J］. Clin Cancer Res, 2002, 8(7): 24432447. ［8］ Vaish V, Rana C, Piplani H, et al. Sulindac and celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer［J］. Cell Biochem Biophys, 2014, 68(2): 301319. DOI: 10.1007/s1201301397118. ［9］ Yang Y, Yan J, Huang Y, et al. The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamouscell carcinoma［J］. Biomed Pharmacother, 2015, 70: 181189. DOI: 10.1016/j.biopha.2015.01.018.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong.Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data[J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86.
[4]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng.Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection[J]. Journal of International Oncology, 2023, 50(12): 711-716.
[5]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin.Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging[J]. Journal of International Oncology, 2023, 50(11): 655-660.
[6]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun.Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model[J]. Journal of International Oncology, 2022, 49(9): 532-536.
[7]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying.Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses[J]. Journal of International Oncology, 2022, 49(8): 459-463.
[8]	Cai Gangxiang, Li Jing, Xu Bin.Advances in neoadjuvant immunotherapy for lung cancer[J]. Journal of International Oncology, 2022, 49(6): 366-370.
[9]	Zhang Jingxian, Yi Dan, Li Xiaojiang.Application of antibody-drug conjugates in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(5): 296-301.
[10]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei.Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer[J]. Journal of International Oncology, 2022, 49(4): 247-251.
[11]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145.
[12]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming.Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(2): 111-115.
[13]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia.Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy[J]. Journal of International Oncology, 2022, 49(12): 718-723.
[14]	Zhang Hongjiao, Jiang Jie, Huang Wei.Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis[J]. Journal of International Oncology, 2022, 49(1): 51-55.
[15]	Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao.Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer[J]. Journal of International Oncology, 2021, 48(9): 523-526.